While Apogee Therapeutics Inc has overperformed by 1.94%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, APGE fell by -14.17%, with highs and lows ranging from $63.50 to $26.20, whereas the simple moving average fell by -9.57% in the last 200 days.
On July 07, 2025, BTIG Research Reiterated Apogee Therapeutics Inc (NASDAQ: APGE) to Buy. A report published by Citigroup on March 13, 2025, Initiated its previous ‘Buy’ rating for APGE. Canaccord Genuity also rated APGE shares as ‘Buy’, setting a target price of $89 on the company’s shares in an initiating report dated November 25, 2024. BofA Securities Initiated an Buy rating on May 10, 2024, and assigned a price target of $80. BTIG Research initiated its ‘Buy’ rating for APGE, as published in its report on December 20, 2023. Wedbush’s report from August 08, 2023 suggests a price prediction of $40 for APGE shares, giving the stock a ‘Outperform’ rating. TD Cowen also rated the stock as ‘Outperform’.
Analysis of Apogee Therapeutics Inc (APGE)
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Apogee Therapeutics Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -27.85% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 15.82, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and APGE is recording an average volume of 877.15K. On a monthly basis, the volatility of the stock is set at 7.07%, whereas on a weekly basis, it is put at 6.85%, with a loss of -0.92% over the past seven days. Furthermore, long-term investors anticipate a median target price of $96.75, showing growth from the present price of $38.88, which can serve as yet another indication of whether APGE is worth investing in or should be passed over.
How Do You Analyze Apogee Therapeutics Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 37.32%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 88.24% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
